TGFB2 and neoplasm: Belagenpumatucel‐L, a nonviral TGF‐β2 antisense gene‐modified allogeneic tumor vaccine designed to enhance tumor antigen recognition by virtue of TGF‐β2 inhibition, showed safety in phase II advanced NSCLC clinical trial and further showed enhanced survival rate [229, 230].